Genomic and prognostic heterogeneity among RAS/BRAF<sup>V600E</sup> /TP53 co-mutated resectable colorectal liver metastases.

Mol Oncol · 2021 · PMC8024718 · PMID 33325154

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Our study cannot conclude on the independent prognostic value of CNA heterogeneity and TP53 mutations in patients with RAS‐ mutated CRLM, although there was a significant trend for poorer patient survival in the RAS/BRAF V600E /TP53 co‐mutated/high CNA heterogeneity group versus co‐mutated/low heterogeneity versus remaining patients.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.